MYB

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

Retrieved on: 
水曜日, 4月 10, 2024
Research, Venture Capital, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, CREB-binding protein, NF2, Dexamethasone, FDA, MYC, TGI, Cancer, Bone marrow, Abdomen, Multiple myeloma, Mouse, MYB, Mesothelioma, EP300, Streets of Rage, Doctor of Philosophy, IND, Glomus tumor, TEAD, FMRP, Therapy, BRAF, CBP, Thomas Jefferson University, Patient, Neurofibromatosis, Hippopotamus, Neoplasm, Standard of care, AACR, E1A, IRF4

Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.

Key Points: 
  • Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego.
  • Multiple myeloma is an aggressive blood cancer derived from malignant plasma cells in the bone marrow.
  • "We are excited to begin our Phase 1 study of OPN-6602 in patients with multiple myeloma this summer.
  • Malignant mesothelioma is a rare and aggressive cancer that primarily affects the lining of the lungs or abdomen.

Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program®

Retrieved on: 
火曜日, 1月 30, 2024
Partnership, MYB, RNA, Oncogene, Therapy, Leukemia & Lymphoma Society, Patient, LLS, Leukemia, Bone marrow, TAP, CSO

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company's therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.
  • "We are honored by the support and recognition of LLS's Therapy Acceleration Program.
  • LLS's strategic investment in Rgenta continues to bolster our confidence in the potential of our pipeline of oral, small-molecule RNA-targeting medicines," commented Simon Xi, Ph.D., CEO of Rgenta.
  • "We look forward to tapping into the extensive clinical expertise and resources from LLS to accelerate the development of our RNA-targeting MYB inhibitor molecules."

Remix Therapeutics to Present Preclinical Data Demonstrating MYB mRNA Degradation in AML at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

Retrieved on: 
木曜日, 12月 7, 2023
Syndrome, Disease, AML, Biotechnology, Messenger, ASH, Remaster, Hematology, Society, MYB, Patient, Therapy, Acute myeloid leukemia, RNA, Vaccine

WATERTOWN, Mass., Dec. 7, 2023 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to modulate RNA processing and address underlying drivers of disease, today announced an upcoming presentation introducing REM-422, the Company's potent, selective, oral small molecule messenger RNA (mRNA) degrader, as a potential treatment for MYB-driven cancers. Data describing the activity of REM-422 in AML xenograft models will be highlighted at the 65th American Society of Hematology Annual Meeting and Exposition (ASH), taking place from December 9-12, 2023 in San Diego. Results demonstrate oral dosing of REM-422 degrades MYB mRNA, inducing anti-leukemic activity in multiple xenograft models.

Key Points: 
  • Data describing the activity of REM-422 in AML xenograft models will be highlighted at the 65th American Society of Hematology Annual Meeting and Exposition (ASH), taking place from December 9-12, 2023 in San Diego.
  • Results demonstrate oral dosing of REM-422 degrades MYB mRNA, inducing anti-leukemic activity in multiple xenograft models.
  • "These compelling data support the therapeutic rationale of targeting MYB with REM-422 as a potential treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix Therapeutics.
  • Details for the poster presentation are as follows:
    Title: REM-422, a potent, selective, oral small molecule mRNA degrader of the MYB oncogene, demonstrates anti-tumor activity in mouse xenograft models of AML

Powered by Its Industry-Leading Comprehensive Multi-Omic Database, Caris Life Sciences to Showcase Extensive Research at ASCO 2023

Retrieved on: 
火曜日, 5月 23, 2023
Consensus, DSCR1, Pancreatic cancer, PDAC, Database, GIST, Abstract, ICIS, TMB, Genomics, Glioma, Neoplasm, FACP, Aggression, MSS, Cancer, Intelligence, MYB, Prognosis, MBA, Research, NSCLC, Biomarker, Lung cancer, Cetuximab, ASCO, American Society of Clinical Oncology, POA, Patient, Machine learning, Colorectal cancer, Medicine, Annual general meeting, Diagnosis, MSI-H, Health, Gastrointestinal stromal tumor, Society, Pharmaceutical industry, Medical imaging, Nursing

IRVING, Texas, May 23, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present 42 studies across more than 30 solid tumor types at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting from June 2-6, 2023 (Booth #13081). The findings demonstrate the power of Caris' comprehensive clinico-genomic database that enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan, and response to treatment.

Key Points: 
  • "The findings of these studies illustrate the power of comprehensive molecular profiling to identify molecular changes that may affect tumor behavior and patient outcomes.
  • The research further illustrates the emerging role of artificial intelligence in informing patient care.
  • (Abstract: 3535; Poster Board: 235)
    Poster and abstract summaries highlighting this research will be available onsite at Caris' booth 13081.
  • The full abstracts will be available on May 25, 2023, at 5 PM EDT through the ASCO website .

Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer

Retrieved on: 
木曜日, 1月 5, 2023
Cancer, IDH, Hoffmann-La Roche, Providence, Pharmacia, CMO, Biotechnology, Therapy, Genentech, Lymphatic system, Pyruvate kinase, Janssen Pharmaceuticals, Disease, Roger Williams Medical Center, Patient, Providence VA Medical Center, Entrepreneurship, Internal medicine, Bristol Myers Squibb, University, AML, Large-cell lung carcinoma, Pyruvate kinase deficiency, BRAF, No. 90 (Signals) Group RAF, MYB, Oncology, RNA, EGFR, Pharmaceutical industry, Cholangiocarcinoma

CAMBRIDGE, Mass., Jan. 5, 2023 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Christopher Bowden, M.D., as Chief Medical Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 5, 2023 /PRNewswire/ -- Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the appointment of Christopher Bowden, M.D., as Chief Medical Officer.
  • "We are especially pleased to welcome Chris to the Remix team as his wealth of strategic medical and corporate experience are ideally suited for this role.
  • We look forward to leveraging his extensive clinical expertise as we advance programs from our REMaster platform toward the clinic," said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics.
  • Dr. Bowden joins Remix from Agios, where he served as a Strategic Advisor and Chief Medical Officer (CMO) from 2014-2022.

Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data

Retrieved on: 
月曜日, 12月 6, 2021
Patient, Volunteering, Review, Safety, Half-life, HBG, PK, Fetal hemoglobin, Sickle cell disease, Fulcrum, KOL, HBF, Thalassemia, Pharmacokinetics, Doctor of Philosophy, Disease, BCL11A, MAD, Eye, Hematology, Nasdaq, Genetics, H3K27me3, GLOBE, Adult, SAD, RNA transfection, Mortality, Therapy, Hemoglobinopathy, MYB, Dietary supplement, Pharmaceutical industry, Vaccine

Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14.

Key Points: 
  • Data from the 20mg and 30mg dose cohorts demonstrated a mean 5.6-fold induction and a mean 6.2-fold induction in HBG mRNA, respectively, at day 14.
  • These increases were higher than those observed in the previously reported 2, 6 and 10mg dose cohorts.
  • In preclinical studies of FTX-6058, increases in HBG mRNA have consistently translated to the same fold increases in HbF protein.
  • The data also showed higher-fold induction of HBG mRNA at the higher doses, with FTX-6058 achieving maximal rate of HBG mRNA induction in the 20mg and 30mg cohorts.